Phyllis Whiteley, PhD., is a Venture Partner with Wildcat Venture Partners where she provides hands-on leadership in building, investing, and creating companies in the digital health space. Phyllis’ career is founded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She has founded and built multiple companies in the United States and abroad.
Her executive expertise includes strategic planning, financing, partnerships, restructuring, building executive teams and M&A. Prior to joining Wildcat Venture Partners and Mohr Davidow Ventures, Phyllis was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for Roche. Over her ten-year career with Roche she held various positions in Business Development based in Basel, Switzerland coupled with R&D leadership positions in the US. Phyllis also held a Senior Research Immunology role with Merck.
Phyllis is dedicated to helping social entrepreneurs address the problems of poverty, empower women, and build resilience to climate change. She sits on the boards of the Personalized Medicine Coalition, UCSF Leadership Council for Global Health, University of Michigan School of Nursing Board for Science and Innovation, and chairs the advisory board for the University of Texas Horizon Fund. Phyllis also serves on the board of Alydia Health, a medical device company treating Post Partum Hemorrhage around the world, and is a Global Social Benefits Mentor at Santa Clara University.
Phyllis holds a BA in Chemistry and Ph.D. in Pharmacology from Washington University, St. Louis, Missouri.
Phyllis’ current portfolio board seats include Carrum Health, Balance Therapeutics and One Spot.
Phyllis’ prior board seats include Analyte Health,CardioDx,Raindance (acquired by BioRad), Sequenta (acquired by Adaptive Biotechnologies), and Verinata (acquired by Illumina).